Medeor Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• MDR-101 · Pulmonology / Rare Genetic Lung Disease
  MDR-101 is a gene therapy that delivers a functional copy of the ABCA3 gene to restore surfactant production in patients with ABCA3-deficient interstitial lung disease.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Medeor Therapeutics, Inc. portfolio CI brief
• Medeor Therapeutics, Inc. pipeline updates RSS